Fleroxacin, a fluoroquinolone derivative with a broad antibacterial spectrum and potent activity in vitro against gram-negative and many gram-positive bacteria, was the subject of a study by Reigner and Welker (A-34). The objectives of their study were to estimate the typical values of clearance over systemic availability (CL/F) and the volume of distribution over systemic availability (V/F) after the administration of therapeutic doses of fleroxacin and to identify factors that influence the disposition of fleroxacin and to quantify the degree to which they do so. Subjects were 172 healthy male and female volunteers and uninfected patients representing a wide age range. Among the data analyzed were the following measurements (ml/min) of CL/F and creatinine clearance (CLcr). According to the authors, previous studies have shown that there is a correlation between the two variables.

CL/F CLer CL/F CLer CL/F CLer CL/F CLer 137.000 96.000 77.000 67.700 152.000 109.000 132.000 111.000 106.000 83.000 57.000 51.500 100.000 82.000 94.000 118.000 165.000 100.000 69.000 52.400 86.000 88.000 90.000 111.000 127.000 101.000 69.000 65.900 69.000 67.000 87.000 124.000 139.000 116.000 76.000 60.900 108.000 68.700 48.000 10.600 102.000 78.000 77.000 93.800 77.000 83.200 26.000 9.280 72.000 84.000 66.000 73.800 85.000 72.800 54.000 12.500 86.000 81.000 53.000 99.100 89.000 82.300 36.000 9.860 85.000 77.000 26.000 110.000 105.000 71.100 26.000 4.740 122.000 102.000 89.000 99.900 66.000 56.000 39.000 7.020 76.000 80.000 44.000 73.800 73.000 61.000 27.000 6.570 57.000 67.000 27.000 65.800 64.000 79.500 36.000 13.600 62.000 41.000 96.000 109.000 26.000 9.120 15.000 7.600 90.000 93.000 102.000 76.800 29.000 8.540 138.000 100.000